Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two Year Prospective, Interventional Single-Centre Trial
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.